1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (p,p'-DDE) disrupts the estrogen-androgen balance regulating the growth of hormone-dependent breast cancer cells

Breast Cancer Research

Volumn 10, Issue 1, 2008, Pages

  Aubé, Michel ^a   Larochelle, Christian ^a   Ayotte, Pierre ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 DICHLORO 2,2 BIS(4 CHLOROPHENYL)ETHYLENE; ANDROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; INSECTICIDE;

ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CELL CYCLE; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; DICHLORODIPHENYL DICHLOROETHYLENE; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; INSECTICIDES; RECEPTORS, ANDROGEN;

EID: 44849124181     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1862     Document Type: Article

References (59)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001, 37(Suppl 8):S4-66. 10.1016/S0959-8049(01)00267-2, 11602373.
2. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004, 96:1856-1865.
3. Kurebayashi J, Otsuki T, Kunisue H, Tanaka K, Yamamoto S, Sonoo H. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin Cancer Res 2000, 6:512-518.
4. Khan SA, Rogers MA, Khurana KK, Siddiqui JF. Oestrogen receptor expression in normal breast epithelium. Eur J Cancer 2000, 36(Suppl 4):S27-S28. 10.1016/S0959-8049(00)00211-2, 11056304.
5. Boyd NF, O'Sullivan B, Campbell JE, Fishell E, Simor I, Cooke G, Germanson T. Mammographic signs as risk factors for breast cancer. Br J Cancer 1982, 45:185-193.
6. Wallgren A, Baral E, Glas U, Karnström L, Nordenskiöld B, Theve NO, Silfverswärd C. Adjuvant tamoxifen treatment in postmenopausal patients with operable breast cancer. J Steroid Biochem 1985, 23:1161-1162. 10.1016/0022-4731(85)90037-8, 3912623.
7. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371-1388. 10.1093/jnci/90.18.1371, 9747868.
8. Jorgensen M, Vendelbo B, Skakkebaek NE, Leffers H. Assaying estrogenicity by quantitating the expression levels of endogenous estrogen-regulated genes. Environ Health Perspect 2000, 108:403-412. 1638061, 10811566, 10.2307/3454380.
9. Diel P, Olff S, Schmidt S, Michna H. Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. J Steroid Biochem Mol Biol 2002, 80:61-70. 10.1016/S0960-0760(01)00173-X, 11867264.
10. López-Cervantes M, Torres-Sánchez L, Tobías A, López-Carrillo L. Dichlorodiphenyldichloroethane burden and breast cancer risk: a meta-analysis of the epidemiologic evidence. Environ Health Perspect 2004, 112:207-214. 1241830, 14754575.
11. Mendez MA, Arab L. Organochlorine compounds and breast cancer risk. Pure Appl Chem 2003, 75:1973-2015.
12. Kelce WR, Stone CR, Laws SC, Gray LE, Kemppainen JA, Wilson EM. Persistent DDT metabolite p,p'-DDE is a potent androgen receptor antagonist. Nature 1995, 375:581-585. 10.1038/375581a0, 7791873.
13. Wilson VS, Lambright C, Ostby J, Gray LE. In vitro and in vivo effects of 17beta-trenbolone: a feedlot effluent contaminant. Toxicol Sci 2002, 70:202-211. 10.1093/toxsci/70.2.202, 12441365.
14. Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J 2000, 14:1725-1730. 10.1096/fj.99-0863com, 10973921.
15. Dimitrakakis C, Zhou J, Wang J, Belanger A, LaBrie F, Cheng C, Powell D, Bondy C. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003, 10:292-298. 10.1097/01.GME.0000055522.67459.89, 12851512.
16. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, Tilley WD. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 1995, 52:459-467. 10.1016/0960-0760(95)00005-K, 7748811.
17. Ortmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T, Rabe T. Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol 2002, 16:113-120. 10.1080/713603030, 12012621.
18. Tormey DC, Lippman ME, Edwards BK, Cassidy JG. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med 1983, 98:139-144.
19. Colleoni M, Coates A, Pagani O, Goldhirsch A. Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: still a question?. Cancer Treat Rev 1998, 24:15-26. 10.1016/S0305-7372(98)90068-8, 9606365.
20. Guttes S, Failing K, Neumann K, Kleinstein J, Georgii S, Brunn H. Chlororganic pesticides and polychlorinated biphenyls in breast tissue of women with benign and malignant breast disease. Arch Environ Contam Toxicol 1998, 35:140-147. 10.1007/s002449900361, 9601932.
21. Demers A, Ayotte P, Brisson J, Dodin S, Robert J, Dewailly E. Risk and aggressiveness of breast cancer in relation to plasma organochlorine concentrations. Cancer Epidemiol Biomarkers Prev 2000, 9:161-166.
22. Lapointe J, Labrie C. Role of the cyclin-dependent kinase inhibitor p27(Kip1) in androgen-induced inhibition of CAMA-1 breast cancer cell proliferation. Endocrinology 2001, 142:4331-4338. 10.1210/en.142.10.4331, 11564693.
23. Leung BS, Potter AH. Mode of estrogen action on cell proliferative kinetics in CAMA-1 cells. I. Effect of serum and estrogen. Cancer Invest 1987, 5:187-194. 10.3109/07357908709011735, 3651865.
24. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjöld M, Gustafsson JA. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997, 82:4258-4265. 10.1210/jc.82.12.4258, 9398750.
25. Lipman ML, Stevens AC, Bleackley RC, Helderman JH, McCune TR, Harmon WE, Shapiro ME, Rosen S, Strom TB. The strong correlation of cytotoxic T lymphocyte-specific serine protease gene transcripts with renal allograft rejection. Transplantation 1992, 53:73-79. 10.1097/00007890-199201000-00014, 1733089.
26. Willey JC, Crawford EL, Jackson CM, Weaver DA, Hoban JC, Khuder SA, DeMuth JP. Expression measurement of many genes simultaneously by quantitative RT-PCR using standardized mixtures of competitive templates. Am J Respir Cell Mol Biol 1998, 19:6-17.
27. Ito K, Suzuki T, Akahira J, Moriya T, Kaneko C, Utsunomiya H, Yaegashi N, Okamura K, Sasano H. Expression of androgen receptor and 5alpha-reductases in the human normal endometrium and its disorders. Int J Cancer 2002, 99:652-657. 10.1002/ijc.10394, 12115497.
28. Gillesby BE, Zacharewski TR. pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers. Breast Cancer Res Treat 1999, 56:253-265. 10.1023/A:1006215310169, 10573116.
29. Liao J, Xu X, Wargovich MJ. Direct reprobing with anti-beta-actin antibody as an internal control for western blotting analysis. Biotechniques 2000, 28:216-218.
30. Szelei J, Jimenez J, Soto AM, Luizzi MF, Sonnenschein C. Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology 1997, 138:1406-1412. 10.1210/en.138.4.1406, 9075695.
31. Andersen HR, Andersson AM, Arnold SF, Autrup H, Barfoed M, Beresford NA, Bjerregaard P, Christiansen LB, Gissel B, Hummel R, Jørgensen EB, Korsgaard B, Le Guevel R, Leffers H, McLachlan J, Møller A, Nielsen JB, Olea N, Oles-Karasko A, Pakdel F, Pedersen KL, Perez P, Skakkeboek NE, Sonnenschein C, Soto AM, et al. Comparison of short-term estrogenicity tests for identification of hormone-disrupting chemicals. Environ Health Perspect 1999, 107(Suppl 1):89-108. 1566352, 10229711, 10.2307/3434476.
32. Payne J, Jones C, Lakhani S, Kortenkamp A. Improving the reproducibility of the MCF-7 cell proliferation assay for the detection of xenoestrogens. Sci Total Environ 2000, 248:51-62. 10.1016/S0048-9697(99)00479-9, 10807042.
33. Rasmussen TH, Nielsen F, Andersen HR, Nielsen JB, Weihe P, Grandjean P. Assessment of xenoestrogenic exposure by a biomarker approach: application of the E-Screen bioassay to determine estrogenic response of serum extracts. Environ Health 2003, 2:12. 270076, 14613489, 10.1186/1476-069X-2-12.
34. Sohoni P, Sumpter JP. Several environmental oestrogens are also anti-androgens. J Endocrinol 1998, 158:327-339. 10.1677/joe.0.1580327, 9846162.
35. Zwijsen RM, Klompmaker R, Wientjens EB, Kristel PM, van der BB, Michalides RJ. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit. Mol Cell Biol 1996, 16:2554-2560. 231245, 8649362.
36. Lukas J, Bartkova J, Bartek J. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol 1996, 16:6917-6925. 231695, 8943347.
37. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994, 369:669-671. 10.1038/369669a0, 8208295.
38. Zhang SY, Caamano J, Cooper F, Guo X, Klein-Szanto AJ. Immunohistochemistry of cyclin D1 in human breast cancer. Am J Clin Pathol 1994, 102:695-698.
39. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994, 57:353-361. 10.1002/ijc.2910570311, 8168995.
40. Planas-Silva MD, Shang Y, Donaher JL, Brown M, Weinberg RA. AIB1 enhances estrogen-dependent induction of cyclin D1 expression. Cancer Res 2001, 61:3858-3862.
41. Cicatiello L, Addeo R, Sasso A, Altucci L, Petrizzi VB, Borgo R, Cancemi M, Caporali S, Caristi S, Scafoglio C, Teti D, Bresciani F, Perillo B, Weisz A. Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol Cell Biol 2004, 24:7260-7274. 479712, 15282324, 10.1128/MCB.24.16.7260-7274.2004.
42. Eeckhoute J, Carroll JS, Geistlinger TR, Torres-Arzayus MI, Brown M. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev 2006, 20:2513-2526. 1578675, 16980581, 10.1101/gad.1446006.
43. Poulin R, Simard J, Labrie C, Petitclerc L, Dumont M, Lagace L, Labrie F. Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. Endocrinology 1989, 125:392-399.
44. Valley CC, Métivier R, Solodin NM, Fowler AM, Mashek MT, Hill L, Alarid ET. Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor alpha N terminus. Mol Cell Biol 2005, 25:5417-5428. 1156995, 15964799, 10.1128/MCB.25.13.5417-5428.2005.
45. Fan M, Nakshatri H, Nephew KP. Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation. Mol Endocrinol 2004, 18:2603-2615. 10.1210/me.2004-0164, 15284335.
46. Petrel TA, Brueggemeier RW. Increased proteasome-dependent degradation of estrogen receptor-alpha by TGF-beta1 in breast cancer cell lines. J Cell Biochem 2003, 88:181-190. 10.1002/jcb.10353, 12461787.
47. Lonard DM, Nawaz Z, Smith CL, O'Malley BW. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell 2000, 5:939-948. 10.1016/S1097-2765(00)80259-2, 10911988.
48. Wormke M, Stoner M, Saville B, Safe S. Crosstalk between estrogen receptor alpha and the aryl hydrocarbon receptor in breast cancer cells involves unidirectional activation of proteasomes. FEBS Lett 2000, 478:109-112. 10.1016/S0014-5793(00)01830-5, 10922479.
49. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW. Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA 1999, 96:1858-1862. 26701, 10051559, 10.1073/pnas.96.5.1858.
50. Alarid ET, Bakopoulos N, Solodin N. Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol Endocrinol 1999, 13:1522-1534. 10.1210/me.13.9.1522, 10478843.
51. Andò S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno ML, Lanzino M. Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol 2002, 193:121-128. 10.1016/S0303-7207(02)00105-3, 12161011.
52. Lanzino M, De Amicis F, McPhaul MJ, Marsico S, Panno ML, Andò S. Endogenous coactivator ARA70 interacts with estrogen receptor alpha (ERalpha) and modulates the functional ERalpha/androgen receptor interplay in MCF-7 cells. J Biol Chem 2005, 280:20421-20430. 10.1074/jbc.M413576200, 15772083.
53. Yeh S, Chang C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 1996, 93:5517-5521. 39278, 8643607, 10.1073/pnas.93.11.5517.
54. Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP. Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol 1999, 188:237-244. 10.1002/(SICI)1096-9896(199907)188:3<237::AID-PATH343>3.0.CO;2-8, 10419589.
55. Clarke RB. Human breast cell proliferation and its relationship to steroid receptor expression. Climacteric 2004, 7:129-137. 10.1080/13697130410001713751, 15497901.
56. Birrell SN, Butler LM, Harris JM, Buchanan G, Tilley WD. Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J 2007, 21:2285-2293. 10.1096/fj.06-7518com, 17413000.
57. Prest SJ, May FE, Westley BR. The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J 2002, 16:592-594.
58. Luqmani YA, Campbell T, Soomro S, Shousha S, Rio MC, Coombes RC. Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. Br J Cancer 1993, 67:749-753.
59. Lackey BR, Gray SL, Henricks DM. Crosstalk and considerations in endocrine disruptor research. Med Hypotheses 2001, 56:644-647. 10.1054/mehy.2000.1249, 11399113.